Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza raka endometrium typu G2 (średniego stopnia zaawansowania)
- •Nowotwór ograniczony tylko do błony śluzowej macicy
- •Wiek poniżej 45 lat
- •Silne pragnienie zachowania możliwości posiadania dzieci
- •Podpisana zgoda na udział w badaniu
✗ Disqualifies
- •Nowotwór przeniknął głęboką warstwę macicy
- •Zaawansowana faza choroby (wyżej niż IA)
- •Inne typy raka lub inne nowotwory w organizmie
- •Przeciwwskazania do leczenia zachowawczego lub stosowania leków
- •Ocena, że pacjentka nie powinna mieć dzieci
Simplified criteria — AI translation
Trial details
- Maximum age
- 45 Years
- Last updated (source)
- August 21, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Peking University People's Hospital
Beijing, China
Trial contact
Yiqin Wang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.